Nuri A. Temiz

4.5k total citations · 2 hit papers
43 papers, 2.7k citations indexed

About

Nuri A. Temiz is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Nuri A. Temiz has authored 43 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 15 papers in Cancer Research and 12 papers in Oncology. Recurrent topics in Nuri A. Temiz's work include Cancer Genomics and Diagnostics (12 papers), CRISPR and Genetic Engineering (9 papers) and Genomics and Chromatin Dynamics (7 papers). Nuri A. Temiz is often cited by papers focused on Cancer Genomics and Diagnostics (12 papers), CRISPR and Genetic Engineering (9 papers) and Genomics and Chromatin Dynamics (7 papers). Nuri A. Temiz collaborates with scholars based in United States, Germany and United Kingdom. Nuri A. Temiz's co-authors include Reuben S. Harris, Michael B. Burns, İvet Bahar, Emily K. Law, Duncan Donohue, Brandon Leonard, Michael A. Carpenter, Douglas Yee, Gabriel J. Starrett and William L. Brown and has published in prestigious journals such as Nature, Nucleic Acids Research and Nature Communications.

In The Last Decade

Nuri A. Temiz

42 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

APOBEC3B is an enzymatic source of mutation in breast cancer

2013 639 citations Michael B. Burns, Lela Lackey et al. Nature profile →
Evidence for APOBEC3B mutagenesis in multiple human cancers

2013 559 citations Michael B. Burns, Nuri A. Temiz et al. profile →

Peers

Countries citing papers authored by Nuri A. Temiz

Since Specialization

Citations

This map shows the geographic impact of Nuri A. Temiz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nuri A. Temiz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nuri A. Temiz more than expected).

Fields of papers citing papers by Nuri A. Temiz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nuri A. Temiz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nuri A. Temiz. The network helps show where Nuri A. Temiz may publish in the future.

Co-authorship network of co-authors of Nuri A. Temiz

This figure shows the co-authorship network connecting the top 25 collaborators of Nuri A. Temiz. A scholar is included among the top collaborators of Nuri A. Temiz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nuri A. Temiz. Nuri A. Temiz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors 2024 ·Neuro-Oncology Advances ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Suganth Suppiah, (unknown), Kyle Williams, Mark Sokolowski, (unknown), (unknown), Nuri A. Temiz, Ariel J. Caride, Aditya Bhagwate, (unknown), Jeong‐Heon Lee, Tamás Ördög, Gelareh Zadeh, David A. Largaespada	1
2	DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo 2023 ·International Journal of Molecular Sciences ·(unknown), Prokopios P. Argyris, Michael A. Carpenter, Harshita B. Gupta, Yanjun Chen, Nuri A. Temiz, Yufan Zhou, Cameron Durfee, (unknown), Brenda Koniar, Silvestro G. Conticello, David A. Largaespada, William L. Brown, Hideki Aihara, Rachel I. Vogel, Reuben S. Harris	8
3	Human APOBEC3B promotes tumor development in vivo including signature mutations and metastases 2023 ·Cell Reports Medicine ·Cameron Durfee, Nuri A. Temiz, Rena Levin-Klein, Prokopios P. Argyris, Lene Alsøe, Sergio Carracedo, (unknown), (unknown), (unknown), (unknown), Xingyu Liu, Yu-Hsiu T. Lin, Rachel I. Vogel, Rocı́o Sotillo, Hilde Nilsen, Reuben S. Harris	24
4	Mutational impact of APOBEC3A and APOBEC3B in a human cell line and comparisons to breast cancer 2023 ·PLoS Genetics ·Michael A. Carpenter, Nuri A. Temiz, Mahmoud A. Ibrahim, Matthew C. Jarvis, Margaret R. Brown, Prokopios P. Argyris, William L. Brown, Gabriel J. Starrett, Douglas Yee, Reuben S. Harris	20
5	In Vitro Insertional Mutagenesis Screen Identifies Novel Genes Driving Breast Cancer Metastasis 2022 ·Molecular Cancer Research ·Csaba Miskey, Lacramioara Botezatu, Nuri A. Temiz, Andreas Gogol‐Döring, Áron Bartha, Balázs Győrffy, David A. Largaespada, Zoltán Ivics, Attila Sebe	4
6	PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer 2021 ·Oncogene ·Thu H. Truong, (unknown), (unknown), Nuri A. Temiz, (unknown), Ying Wang, Emilio Cortes-Sanchez, (unknown), (unknown), Thomas Pengo, Katrin P. Guillen, Bryan E. Welm, Camila O. dos Santos, Sucheta Telang, Carol A. Lange, Julie H. Ostrander	26
7	APOBEC3A catalyzes mutation and drives carcinogenesis in vivo 2020 ·The Journal of Experimental Medicine ·Emily K. Law, Rena Levin-Klein, Matthew C. Jarvis, Hyoung Kim, Prokopios P. Argyris, Michael A. Carpenter, Gabriel J. Starrett, Nuri A. Temiz, (unknown), Cameron Durfee, Michael B. Burns, Rachel I. Vogel, Spyridon Stavrou, (unknown), Sandra Wagner, David A. Largaespada, Timothy K. Starr, Susan R. Ross, Reuben S. Harris	83
8	Cancer Stem Cell Phenotypes in ER+ Breast Cancer Models Are Promoted by PELP1/AIB1 Complexes 2018 ·Molecular Cancer Research ·Thu H. Truong, (unknown), Nuri A. Temiz, (unknown), Brian J. Girard, Nicholas J. Brady, Kathryn L. Schwertfeger, Carol A. Lange, Julie H. Ostrander	20
9	Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis 2018 ·Journal of Hepatology ·(unknown), (unknown), Fabrice Daian, María Arechederra, Sylvie Richelme, Nuri A. Temiz, Annie Yim, Bianca Habermann, Rosanna Dono, David A. Largaespada, Flavio Maina	14
10	Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma 2017 ·Cancer Research ·Milcah C. Scott, Nuri A. Temiz, Anne E. Sarver, Rebecca S. LaRue, Susan K. Rathe, Jyotika Varshney, Natalie K. Wolf, Branden S. Moriarity, Timothy D. O’Brien, Logan G. Spector, David A. Largaespada, Jaime F. Modiano, Subbaya Subramanian, Aaron L. Sarver	84
11	Sleeping Beauty Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors 2017 ·Cancer Research ·Barbara R. Tschida, Nuri A. Temiz, (unknown), (unknown), Jesse D. Riordan, (unknown), (unknown), Sandra Wagner, Wendy A. Hudson, Michael A. Linden, Khalid Amin, (unknown), (unknown), Aaron L. Sarver, Ju Dong Yang, Lewis R. Roberts, Joseph H. Nadeau, Adam J. Dupuy, Vincent W. Keng, David A. Largaespada	34
12	The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer 2016 ·Science Advances ·Emily K. Law, Anieta M. Sieuwerts, Kelly LaPara, Brandon Leonard, Gabriel J. Starrett, Amy M. Molan, Nuri A. Temiz, Rachel I. Vogel, Marion E. Meijer‐van Gelder, Fred C.G.J. Sweep, Paul N. Span, John A. Foekens, John W.M. Martens, Douglas Yee, Reuben S. Harris	160
13	Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B 2016 ·PLoS ONE ·(unknown), Gabriel J. Starrett, Jelmar Quist, Nuri A. Temiz, Michael A. Carpenter, Andrew Tutt, Anita Grigoriadis, Reuben S. Harris	23
14	The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis 2016 ·Nature Communications ·Gabriel J. Starrett, Elizabeth M. Luengas, Jennifer L. McCann, Diako Ebrahimi, Nuri A. Temiz, Robin P. Love, Yuqing Feng, Madison B. Adolph, Linda Chelico, Emily K. Law, Michael A. Carpenter, Reuben S. Harris	121
15	APOBEC3B is an enzymatic source of mutation in breast cancer breakdown → 2013 ·Nature ·Michael B. Burns, Lela Lackey, Michael A. Carpenter, Anurag S. Rathore, Allison M. Land, Brandon Leonard, Eric W. Refsland, Delshanee Kotandeniya, Natalia Tretyakova, Jason B. Nikas, Douglas Yee, Nuri A. Temiz, Duncan Donohue, Rebecca M. McDougle, William L. Brown, Emily K. Law, Reuben S. Harris	639
16	The Role of Methylation in the Intrinsic Dynamics of B- and Z-DNA 2012 ·PLoS ONE ·Nuri A. Temiz, Duncan Donohue, Albino Bacolla, Brian T. Luke, Jack Collins	60
17	Novel modulation factor quantifies the role of water molecules in protein interactions 2010 ·Proteins Structure Function and Bioinformatics ·Marta Bueno, Nuri A. Temiz, Carlos J. Camacho	4
18	Electrostatic hot spot on DNA-binding domains mediates phosphate desolvation and the pre-organization of specificity determinant side chains 2010 ·Nucleic Acids Research ·Nuri A. Temiz, Panayiotis V. Benos, Carlos J. Camacho	9
19	Conformational Changes in HIV-1 Reverse Transcriptase Induced by Nonnucleoside Reverse Transcriptase Inhibitor Binding 2004 ·Current HIV Research ·Nicolas Sluis‐Cremer, Nuri A. Temiz, İvet Bahar	111
20	Escherichia coli adenylate kinase dynamics: Comparison of elastic network model modes with mode‐coupling ¹⁵N‐NMR relaxation data 2004 ·Proteins Structure Function and Bioinformatics ·Nuri A. Temiz, Eva Meirovitch, İvet Bahar	80

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact